Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNAP -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (16)	5/29/1998 7:49:00 AM
From: LWolf	Read Replies (1) \| Respond to of 124

RESEARCH ALERT-Vector upgrades Synaptic <SNAP.O> CHICAGO, May 28 (Reuters) - Vector Securities International Inc said Thursday analyst Richard Toth upgraded Synaptic Pharmaceutical Corp. to buy from attractive based on positive Phase II results with its migraine drug. -- Toth said in a report the results of Phase II study, conducted by Synaptic partner Eli Lilly and Co. <LLY.N> suggest good efficacy, "validate Synaptic's technology and elimate near term risk." -- Says Synaptic "is well-partnered, well-financed and well-managed, a rare mix which we believe makes it a compelling small-cap biotech investment." -- Has one-year share price target of $20. -- Stock up two at 15 in afternoon trading. ((Chicago equities news, 312 408 8787, chicago.equities.newsroom@reuters.com)) REUTERS _____________________ I wondered what might have caused the move up in SNAP yesterday.... do you suppose there may be a couple more upgrades coming? would be nice! :)) Laura